Study of SNV1521 with a RAS inhibitor for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination treatment for pancreatic cancer that has spread or cannot be removed with surgery. The goal is to see if the combination can help control the cancer and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have pancreatic cancer that has spread or cannot be surgically removed.
- Your cancer was confirmed by a biopsy or cell sample.
- You have at least one tumor that can be measured on a scan.
- You are in generally good health and can swallow oral medications.
- You are willing to follow the study schedule and use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
This program gives early access to an experimental pill called daraxonrasib for people whose pancreatic cancer has spread and has not responded to previous chemotherapy. It is not a regular clinical trial but a way to try the drug if no other options are available.
This trial tests a new drug that targets a common gene change (RAS) in advanced pancreatic cancer. It combines that drug with other treatments to see if it helps people whose cancer has not responded to or come back after prior therapy.
This trial tests a new drug (DN022150) combined with standard chemotherapy (AG) as a first treatment for advanced or metastatic pancreatic cancer that has a specific gene change called KRAS G12D. It may help people who haven't had other treatments for this stage of cancer.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests whether combining two experimental drugs (GFH375 with GFS202A or GFH276) works better than one drug alone for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It may offer a new option for those who have already tried other treatments.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.